Abiopharma

🔍 MACARTNEY LAWSON (Executive)

Company: Viking Therapeutics, Inc. (VKTX)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 3,150 shares of Common Stock, par value $0.00001 per share (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 51,115.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 20,400 shares of Stock Option (Right to Buy) at $35.42 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | Exercise: 2027-01-02 | equity_swap_involved: false | shares_owned_after: 20,400.00 | transaction_form_type: 4

Footnotes:

• F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.